The survival rate for most cancers has doubled over the last 40 years, with 50% of patients surviving 10 or more years. However, for hard-to-treat cancers the survival rates remain below 14%. The IRC’s approach will increase the efficacy of existing drugs and open the door for new therapeutic agents.
The Engineering and Physical Sciences Research Council (EPSRC) Interdisciplinary Research Collaboration (IRC) in Targeted Delivery for Hard-to-Treat Cancers aims to develop new technologies to effectively deliver drugs for the treatment of three hard-to-treat cancers: mesothelioma, pancreatic cancer and glioblastoma (a brain cancer). The IRC comprises five founding universities, Cambridge, Imperial, UCL, Glasgow and Birmingham, now also joined by Nottingham, Liverpool and Strathclyde.
© 2025 University of Cambridge
